WO2011086141A1 - Souche hôte bactérienne exprimant dsbc recombinant - Google Patents

Souche hôte bactérienne exprimant dsbc recombinant Download PDF

Info

Publication number
WO2011086141A1
WO2011086141A1 PCT/EP2011/050418 EP2011050418W WO2011086141A1 WO 2011086141 A1 WO2011086141 A1 WO 2011086141A1 EP 2011050418 W EP2011050418 W EP 2011050418W WO 2011086141 A1 WO2011086141 A1 WO 2011086141A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
cell
dsbc
antigen binding
Prior art date
Application number
PCT/EP2011/050418
Other languages
English (en)
Inventor
David Paul Humphreys
Original Assignee
Ucb Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma S.A. filed Critical Ucb Pharma S.A.
Publication of WO2011086141A1 publication Critical patent/WO2011086141A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved

Definitions

  • the invention relates to a recombinant bacterial host strain, particularly E. coli.
  • the invention also relates to a method for producing a protein of interest in such a cell.
  • Bacterial cells such as E. coli, are commonly used for producing recombinant proteins. There are many advantages to using bacterial cells, such as E. coli, for producing recombinant proteins particularly due to the versatile nature of bacterial cells as host cells allowing the gene insertion via plasmids. E. coli have been used to produce many recombinant proteins including human insulin.
  • the present invention provides a recombinant gram-negative bacterial cell comprising:
  • b a polynucleotide sequence encoding an antibody or an antigen binding fragment thereof specific for human TNFa.
  • the gram-negative bacterial cell according to the present invention shows advantageous growth and protein production phenotypes.
  • the present invention also provides an expression vector comprising a recombinant polynucleotide encoding DsbC and an antibody or an antigen binding fragment thereof specific for human TNFa.
  • the present invention also provides a method for producing an antibody or an antigen binding fragment thereof specific for human TNFa comprising:
  • Figure 1 shows the construction of a vector for use in producing a cell according to an embodiment of the present invention.
  • Figure 2 shows shows the structure of a compound called CDP870 comprising a modified Fab fragment derived from antibody hTNF40 covalently linked via a cysteine residue to a lysyl-maleimide linker wherein each amino group on the lysyl residue has covalently attached to it a methoxy PEG residue wherein n is about 420.
  • Figure 3 shows the growth profile of anti-TNFa Fab' expressing strain W31 10 and anti- TNFa Fab' and recombinant DsbC expressing strain W3110.
  • Figure 4 shows anti-TNFa Fab' yield from the periplasm (shaded symbols) and supernatant (open unshaded symbols) from anti-TNFa Fab' expressing strain W3110 and anti-TNFa Fab' and recombinant DsbC expressing strain W3110.
  • SEQ ID NO: 1 shows the amino acid sequence of CDRH1 of hTNF40.
  • SEQ ID NO: 2 shows the amino acid sequence of CDRH2 of hTNF40 which is a hybrid CDR wherein the C-terminal six amino acids are from the H2 CDR sequence of a human subgroup 3 germline antibody and the amino acid changes to the sequence resulting from this hybridisation are underlined as follows: WINTYIGEPI YADSVKG.
  • SEQ ID NO: 3 shows the amino acid sequence of CDRH3 of hTNF40.
  • SEQ ID NO: 4 shows the amino acid sequence of CDRL1 of hTNF40.
  • SEQ ID NO: 5 shows the amino acid sequence of CDRL2 of hTNF40.
  • SEQ ID NO: 6 shows the amino acid sequence of CDRL3 of hTNF40.
  • SEQ ID NO: 7 shows the amino acid sequence of CDRH2 of hTNF40.
  • SEQ ID NO: 8 shows the nucleotide and predicted amino acid sequence of the light chain variable region hTNF40-gLl.
  • SEQ ID NO: 9 shows the predicted amino acid sequence of the light chain variable region hTNF40-gLl .
  • SEQ ID NO: 10 shows the nucleotide and predicted amino acid sequence of the light chain variable region hTNF40-gL2.
  • SEQ ID NO: 11 shows the predicted amino acid sequence of the light chain variable region hTNF40-gL2.
  • SEQ ID NO: 12 shows the nucleotide and predicted amino acid sequence of the heavy chain variable region ghlhTNF40.4.
  • SEQ ID NO: 13 shows the predicted amino acid sequence of the heavy chain variable region ghlhTNF40.4.
  • SEQ ID NO: 14 shows the nucleotide and predicted amino acid sequence of the heavy chain variable region gh3hTNF40.4.
  • SEQ ID NO: 15 shows the predicted amino acid sequence of the heavy chain variable region gh3hTNF40.4.
  • SEQ ID NO: 16 shows the nucleotide sequence of a grafted anti-TNFa Fab heavy chain.
  • SEQ ID NO: 17 shows the amino acid sequence of a grafted anti-TNFa Fab heavy chain.
  • SEQ ID NO: 18 shows the nucleotide sequence of a grafted anti-TNFa Fab light chain.
  • SEQ ID NO: 19 shows the amino acid sequence of a grafted anti-TNFa Fab light chain.
  • SEQ ID NO: 20 shows the nucleotide sequence of a grafted anti-TNFa Fab heavy chain.
  • SEQ ID NO: 21 shows the amino acid sequence of a grafted anti-TNFa Fab heavy chain.
  • SEQ ID NO: 22 shows the sequence of the OmpA oligonucleotide adapter.
  • SEQ ID NO: 23 shows the oligonucleotide cassette encoding intergenic sequence 1 (IGS1) for E. coli Fab expression.
  • SEQ ID NO: 24 shows the oligonucleotide cassette encoding intergenic sequence 2 (IGS2) for E. coli Fab expression.
  • SEQ ID NO: 25 shows the oligonucleotide cassette encoding intergenic sequence 3 (IGS3) for E. coli Fab expression.
  • SEQ ID NO: 26 shows the oligonucleotide cassette encoding intergenic sequence 4 (IGS4) for E. coli Fab expression.
  • SEQ ID NO: 27 is the nucleotide sequence of his-tagged DsbC.
  • SEQ ID NO: 28 is the amino acid sequence of his-tagged DsbC.
  • protein and “polypeptide” are used interchangeably herein, unless the context indicates otherwise.
  • Peptide is intended to refer to 10 or less amino acids.
  • polynucleotide includes a gene, DNA, cDNA, RNA, mRNA etc unless the context indicates otherwise.
  • the non-mutated cell or control cell in the context of the present invention means a cell of the same type as the recombinant gram-negative cell of the invention wherein the cell has not been modified to carry the recombinant polynucleotide sequence encoding DsbC and the polynucleotide sequence encoding an antibody or an antigen binding fragment thereof specific for human TNFa.
  • a non-mutated cell may be a wild-type cell and may be derived from the same population of host cells as the cells of the invention before modification to introduce any recombinant polynucleotide sequences.
  • the term "isogenic" in the context of the present invention means that the cell comprises the same or substantially the same nucleic acid sequence(s) compared to wild- type cell except for the recombinant polynucleotide encoding DsbC and the polynucleotide sequence encoding an antibody or an antigen binding fragment thereof specific for human TNFa.
  • the cell according to the present invention comprises no further non-naturally occurring or genetically engineered mutations.
  • the cell according to the present invention may have substantially the same genomic sequence compared to the wild-type cell except for the polynucleotide sequence encoding DsbC and/or the polynucleotide sequence encoding the antibody taking into account any naturally occurring mutations which may occur.
  • the cell according to the present invention may have exactly the same genomic sequence compared to the wild-type cell except for the polynucleotide sequence encoding DsbC and/or the polynucleotide sequence encoding the antibody.
  • the polynucleotide encoding DsbC may be present on a suitable expression vector transformed into the cell and/or integrated into the host cell's genome.
  • the cell of the present invention differs from a wild-type cell due to the inserted polynucleotide sequence encoding the DsbC.
  • the host cell's genome may be isogenic compared to a wild-type cell genome except for the recombinant polynucleotide sequence encoding DsbC.
  • the polynucleotide encoding DsbC is in an expression vector in the cell thereby causing minimal disruption to the host cell's genome.
  • the polynucleotide encoding the antibody or an antigen binding fragment thereof specific for human TNFa may be contained within a suitable expression vector transformed into the cell and/or integrated into the host cell's genome.
  • the cell of the present invention differs from a wild-type cell due to the inserted polynucleotide sequence encoding the antibody.
  • the host cell's genome may be isogenic compared to a wild-type cell genome except for the polynucleotide sequence encoding the antibody.
  • the polynucleotide encoding the protein of interest is in an expression vector in the cell thereby causing minimal disruption to the host cell's genome.
  • DsbC and the polynucleotide encoding the antibody are inserted into the host's genome.
  • the cell of the present invention differs from a wild-type cell due to the inserted recombinant polynucleotide encoding DsbC and the polynucleotide sequence encoding the antibody.
  • the host cell's genome may be isogenic compared to a wild-type cell genome except for the recombinant polynucleotide sequence encoding DsbC and the polynucleotide sequence encoding the antibody.
  • the recombinant polynucleotide encoding DsbC and the polynucleotide encoding the antibody are present in the same or different expression vectors in the cell thereby causing minimal disruption to the host cell's genome.
  • the cell's genome may be substantially the same or exactly the same compared to the genome of a wild-type cell.
  • wild-type in the context of the present invention means a strain of a gram-negative bacterial cell as it may occur in nature or may be isolated from the environment, which does not carry any recombinant sequences or genetically engineered mutations.
  • An example of a wild-type strain of E. coli is W3110, such as W3110 K-12 strain.
  • the present inventors have provided a recombinant gram-negative bacterial cell suitable for expressing an antibody or an antigen binding fragment thereof specific for human TNFa which comprises a recombinant polynucleotide encoding DsbC.
  • DsbC is a prokaryotic protein found in the periplasm of E.coli which catalyzes the formation of disulphide bonds in E.coli.
  • DsbC has an amino acid sequence length of 236 (including signal peptide) and a molecular weight of 25.6 KDa (UniProt No. P0AEG6).
  • DsbC was first identified in 1994 (Missiakas et al.
  • the Escherichia coli dsbC (xprA) gene encodes a periplasmic protein involved in disulfide bond formation, The EMBO Journal vol 13, no 8, p2013-2020, 1994 and Shevchik et al.
  • DsbC a periplasmic protein of Erwinia chrysanthemi and Escherichia coli with disulfide isomerase activity
  • WO98/56930 discloses a method for producing heterologous disulfide bond-containing polypeptides in bacterial cells wherein a prokaryotic disulfide isomerase, such as DsbC or DsbG is co-expressed with a eukaryotic polypeptide.
  • a prokaryotic disulfide isomerase such as DsbC or DsbG is co-expressed with a eukaryotic polypeptide.
  • US6673569 discloses an artificial operon comprising polynucleotides encoding each of DsbA, DsbB, DsbC and DsbD for use in producing a foreign protein.
  • EP0786009 discloses a process for producing a heterologous polypeptide in bacteria wherein the expression of nucleic acid encoding DsbA or DsbC is induced prior to the induction of expression of nucleic acid encoding the heterologous polypeptide.
  • a gram-negative bacterial cell comprising a recombinant polynucleotide encoding DsbC and a polynucleotide encoding an anti-TNFa antibody.
  • the cells according to the present invention comprise a recombinant polynucleotide encoding DsbC.
  • a "recombinant polypeptide” refers to a protein that is constructed or produced using recombinant DNA technology.
  • the polynucleotide sequence encoding DsbC may be identical to the endogenous sequence encoding DsbC found in bacterial cells.
  • the recombinant polynucleotide sequence encoding DsbC is a mutated version of the wild-type DsbC sequence, for example having a restriction site removed, such as an EcoRI site, and/or a sequence encoding a his-tag.
  • SEQ ID NO: 27 An example modified DsbC sequence for use in the present invention is shown in SEQ ID NO: 28, which encodes the his-tagged DsbC sequence shown in SEQ ID NO:28.
  • the present inventors have identified that the selection of the expression of recombinant polynucleotide encoding DsbC in a bacterial cell, provides an improved host for expressing an antibody or an antigen binding fragment thereof specific for human TNFa.
  • the cells provided by the present invention have improved cell health and growth phenotype compared to wild-type bacterial cells.
  • the cells according to the present invention exhibit improved antibody production yield compared to wild-type bacterial cells.
  • the improved protein yield may be the rate of protein production and/or the duration of protein production from the cell.
  • the improved protein yield may be the periplasmic protein yield and/or the supernatant protein yield.
  • the recombinant bacterial cells may be capable of faster rate of production of the antibody and, therefore, the same quantity of a protein of interest may be produced in a shorter time compared to a non-mutated bacterial cell.
  • the faster rate of production of a protein of interest may be especially significant over the initial period of growth of the cell, for example over the first 5, 10, 20 or 30 hours post induction of protein expression.
  • the cells according to the present invention preferably express a maximum yield in the periplasm and/or media of approximately l .Og/L, 1.5g/L, 1.8g/L, 2.0g/L, 2.4g/L, 2.5g/L, 3.0g/L, 3.5g/L or 4.0g/L of the antibody.
  • one or more proteins capable of facilitating protein folding such as FkpA, Skp, SurA, PPiA and PPiD; and/or
  • one or more protein capable of facilitating protein secretion or translocation such as SecY, SecE, SecG, SecYEG, SecA, SecB, FtsY and Lep; and/or
  • one or more proteins capable of facilitating disulphide bond formation such as DsbA, DsbB, DsbD, DsbG.
  • One of more of the above proteins may be integrated into the cell's genome and/or inserted in an expression vector.
  • one or more proteins capable of facilitating protein folding such as FkpA, Skp, SurA, PPiA and PPiD;
  • one or more protein capable of facilitating protein secretion or translocation such as SecY, SecE, SecG, SecYEG, SecA, SecB, FtsY and Lep;
  • one or more proteins capable of facilitating disulphide bond formation such as DsbA, DsbB, DsbD, DsbG.
  • mutated Tsp gene wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene;
  • a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity
  • mutated ptr gene wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene;
  • a mutated OmpT gene wherein the mutated OmpT gene encodes a OmpT protein having reduced protease activity or is a knockout mutated OmpT gene.
  • the gram-negative bacterial cell according to the present invention does not carry a knockout mutated Tsp gene, such as being deficient in chromosomal Tsp.
  • the gram-negative bacterial cell according to the present invention does not carry a knockout mutated ompT gene, such as being deficient in chromosomal ompT.
  • the gram-negative bacterial cell according to the present invention does not carry a knockout mutated degP gene, such as being deficient in chromosomal degP. In one embodiment the gram-negative bacterial cell according to the present invention does not carry a mutated degP gene.
  • the gram-negative bacterial cell according to the present invention does not carry a knockout mutated ptr gene, such as being deficient in chromosomal ptr.
  • the gram-negative bacterial cell according to the present invention does not carry a mutated spr gene.
  • Any suitable gram-negative bacterium may be used as the parental cell for producing the recombinant cell of the present invention.
  • Suitable gram-negative bacterium include Salmonella typhimurium, Pseudomonas fluorescens, Erwinia carotovora, Shigella, Klebsiella pneumoniae, Legionella pneumophila, Pseudomonas aeruginosa, Acinetobacter baumannii and E. coli.
  • the parental cell is E. coli.
  • Any suitable strain of E. coli may be used in the present invention but preferably a wild- type W3110 strain, such as K-12 W3110, is used.
  • a drawback associated with strains previously created and used to express recombinant proteins involves the use of mutations of genes involved in cell metabolism and DNA replication such as, for example phoA, fliuA, lac, rec, gal, ara, org, thi and pro in E. coli strains. These mutations may have many deleterious effects on the host cell including effects on cell growth, stability, recombinant protein expression yield and toxicity. Strains having one or more of these genomic mutations, particularly strains having a high number of these mutations, may exhibit a loss of fitness which reduces bacterial growth rate to a level which is not suitable for industrial protein production.
  • any of the above genomic mutations may affect other genes in cis and/or in trans in unpredictable harmful ways thereby altering the strain's phenotype, fitness and protein profile.
  • the use of heavily mutated cells is not generally suitable for producing recombinant proteins for commercial use, particularly therapeutics, because such strains generally have defective metabolic pathways and hence may grow poorly or not at all in minimal or chemically defined media.
  • the cells carry only the minimal mutations to introduce the recombinant polynucleotide encoding DsbC and the polynucleotide sequence encoding the antibody.
  • the polynucleotide sequence encoding DsbC and/or the polynucleotide sequence encoding the antibody are inserted into the cell's genome only minimal mutations are made to the cell's genome to introduce recombinant polynucleotide encoding DsbC and/or the antibody.
  • the genome is preferably isogenic to a wild-type cell genome.
  • the cells do not carry any other mutations which may have deleterious effects on the cell's growth and/or ability to express a protein of interest. Accordingly, one or more of the recombinant host cells of the present invention may exhibit improved protein expression and/or improved growth characteristics compared to cells comprising genetically engineered mutations to the genomic sequence.
  • the cells provided by the present invention are also more suitable for use to produce therapeutic proteins compared to cells comprising disruptions to the cell genome.
  • the cell is isogenic to a wild-type E. coli cell except for the recombinant polynucleotide encoding DsbC and the polynucleotide sequence encoding an antibody or an antigen binding fragment thereof specific for human TNFa. More preferably the cell according to the present invention is isogenic to an E. coli strain W3110 except for the recombinant polynucleotide encoding DsbC and the polynucleotide sequence encoding an antibody or an antigen binding fragment thereof specific for human TNFa.
  • the cell provided by the present invention comprises a polynucleotide sequence encoding an antibody specific for TNFa.
  • the antibody may be a multi-valent, multi- specific, humanized, fully human or chimeric antibody.
  • the antibody can be from any species but is preferably derived from a monoclonal antibody, a human antibody, or a humanized fragment.
  • the antibody can be derived from any class (e.g. IgG, IgE, IgM, IgD or IgA) or subclass of immunoglobulin molecule and may be obtained from any species including for example mouse, rat, shark, rabbit, pig, hamster, camel, llama, goat or human. Parts of the antibody fragment may be obtained from more than one species for example the antibody fragments may be chimeric. In one example the constant regions are from one species and the variable regions from another.
  • the antibody may comprise: a complete antibody molecule, having full length heavy and light chains; a fragment thereof, such as a VH, VL, VHH, Fab, modified Fab, Fab', F(ab') 2 or Fv fragment; a light chain or heavy chain monomer or dimer; a single chain antibody, e.g. a single chain Fv in which the heavy and light chain variable domains are joined by a peptide linker, Fab-Fv, or a dual specificity antibody, such as a Fab-dAb, as described in PCT/GB2008/003331.
  • the heavy and light chain variable regions may be combined with other antibody domains as appropriate.
  • the anti-TNFa antibody is preferably an antibody derived from a mouse monoclonal antibody hTNF40 as described in WO01/094585 (the contents of which are incorporated herein by reference).
  • the antibody having specificity for human TNFoc comprises a heavy chain wherein the variable domain comprises a CDR having the sequence shown in SEQ ID NO:l for CDRH1, the sequence shown in SEQ ID NO:2 or SEQ ID NO:7 for
  • the antibody comprises a light chain wherein the variable domain comprises a CDR having the sequence shown in SEQ ID NO: 4 for CDRLl, the sequence shown in SEQ ID NO: 5 for CDRL2 or the sequence shown in SEQ ID NO: 6 for CDRL3.
  • SEQ ID NO:2 consists of a hybrid CDR.
  • the hybrid CDR comprises part of heavy chain CDR2 from mouse monoclonal antibody hTNF40 (SEQ ID NO:7) and part of heavy chain CDR2 from a human group 3 germline V region sequence.
  • the antibody comprises a heavy chain wherein the variable domain comprises a CDR having the sequence shown in SEQ ID NO:l for CDRHl, the sequence shown in SEQ ID NO:2 or SEQ ID NO: 7 for CDRH2 or the sequence shown in SEQ ID NO: 3 for CDRH3 and a light chain wherein the variable domain comprises a CDR having the sequence shown in SEQ ID NO:4 for CDRLl, the sequence shown in SEQ ID NO:5 for CDRL2 or the sequence shown in SEQ ID NO:6 for CDRL3.
  • the antibody comprises SEQ ID NO:l for CDRHl, SEQ ID NO: 2 or SEQ ID NO:7 for CDRH2, SEQ ID NO:3 for CDRH3, SEQ ID NO:4 for CDRL1, SEQ ID NO:5 for CDRL2 and SEQ ID NO:6 for CDRL3.
  • the antibody comprises SEQ ID NO:2 for CDRH2.
  • the antibody is preferably a CDR-grafted antibody molecule and typically the variable domain comprises human acceptor framework regions and non-human donor CDRs.
  • the antibody comprises the light chain variable domain hTNF40-gLl (SEQ ID NO:8) and the heavy chain variable domain gh3hTNF40.4 (SEQ ID NO: 14).
  • the antibody is a Fab fragment.
  • the Fab fragment has a heavy chain comprising or consisting of the sequence given as SEQ ID NO: 17 and a light chain comprising or consisting of the sequence given as SEQ ID NO: 19.
  • the amino acid sequences given in SEQ ID NO: 17 and SEQ ID NO: 19 are preferably encoded by the nucleotide sequences given in SEQ ID NO: 16 and SEQ ID NO: 18, respectively.
  • the antibody is a modified Fab fragment wherein the modification is the addition to the C-terminal end of its heavy chain one or more amino acids to allow the attachment of an effector or reporter molecule.
  • the additional amino acids form a modified hinge region containing one or two cysteine residue to which the effector or reporter molecule may be attached.
  • Such a modified Fab fragment preferably has a heavy chain comprising or consisting of the sequence given as SEQ ID NO:21 and the light chain comprising or consisting of the sequence given as SEQ ID NO: 19.
  • the amino acid sequence given in SEQ ID NO:21 is preferably encoded by the nucleotide sequence given in SEQ ID NO:20.
  • the antibody may be a variant antibody, which has an improved affinity for TNF .
  • variants can be obtained by a number of affinity maturation protocols including mutating the CDRs (Yang et al , J. Mol. Biol., 254, 392-403, 1995), chain shuffling (Marks et al, Bio/Technology, 10, 779-783, 1992), use of mutator strains of E. coli (Low et al, J. Mol. Biol., 250, 359-368, 1996), DNA shuffling (Patten et al, Curr. Opin. BiotechnoL, 8, 724-733, 1997), phage display (Thompson et al, J. Mol. Biol, 256, 77-88, 1996) and sexual PCR (Crameri et al, Nature, 391, 288-291, 1998). Vaughan et al. ⁇ supra) discusses these methods of affinity maturation.
  • the cell according to the present invention comprises DNA sequence encoding the antibody.
  • the DNA sequence encodes the heavy and the light chain of the antibody.
  • the DNA sequence encodes a light chain and comprises the sequence shown in SEQ ID NO: 8 (hTNF40-gLl) or SEQ ID NO: 10 (h- TNF-40-gL2) or a degenerate equivalent thereof.
  • the DNA sequence encodes a heavy chain and comprises the sequence shown in SEQ ID NO: 12 (ghlhTNF40.4) or SEQ ID NO: 14 (gh3hTNF40.4) or a degenerate equivalent thereof.
  • the cell comprises the DNA sequence shown in SEQ ID NO: 20 and the DNA sequence shown in SEQ ID NO: 18.
  • the DNA sequence of the may comprise synthetic DNA, for instance produced by chemical processing, cDNA, genomic DNA or any combination thereof.
  • the antibody preferably has a binding affinity of at least 0.85x10 "10 M, more preferably at least 0.75x10 "10 M and most preferably at least 0.5x10 "10 M. (It is worth noting that the preferred humanised antibody, has an affinity of about 0.5x10 "10 M, which is better than the affinity of the murine monoclonal antibody from which it is derived.
  • the murine antibody has an affinity of about 0.85x10 "10 M.)
  • the constant region domains of the antibody may be selected having regard to the proposed function of the antibody molecule, and in particular the effector functions which may be required.
  • the constant region domains may be human IgA, IgD, IgE, IgG or IgM domains.
  • human IgG constant region domains may be used, especially of the IgGl and IgG3 isotypes when the antibody molecule is intended for therapeutic uses and antibody effector functions are required.
  • IgG2 and IgG4 isotypes may be used when the antibody molecule is intended for therapeutic purposes and antibody effector functions are not required, e.g. for simply blocking TNFa activity.
  • the antibody may be useful in the treatment of diseases or disorders including inflammatory diseases and disorders, immune disease and disorders, fibrotic disorders and cancers.
  • inflammatory disease or "disorder” and "immune disease or disorder” includes rheumatoid arthritis, psoriatic arthritis, still's disease, Muckle Wells disease, psoriasis, Crohn's disease, ulcerative colitis, SLE (Systemic Lupus Erythematosus), asthma, allergic rhinitis, atopic dermatitis, multiple sclerosis, vasculitis, Type I diabetes mellitus, transplantation and graft- versus-host disease.
  • fibrotic disorder includes idiopathic pulmonary fibrosis (IPF), systemic sclerosis (or scleroderma), kidney fibrosis, diabetic nephropathy, IgA nephropathy, hypertension, end-stage renal disease, peritoneal fibrosis (continuous ambulatory peritoneal dialysis), liver cirrhosis, age-related macular degeneration (ARMD), retinopathy, cardiac reactive fibrosis, scarring, keloids, burns, skin ulcers, angioplasty, coronary bypass surgery, arthroplasty and cataract surgery.
  • IPF idiopathic pulmonary fibrosis
  • systemic sclerosis or scleroderma
  • kidney fibrosis diabetic nephropathy
  • IgA nephropathy IgA nephropathy
  • hypertension end-stage renal disease
  • peritoneal fibrosis continuous ambulatory peritoneal dialysis
  • liver cirrhosis liver cirrhos
  • cancer includes a malignant new growth that arises from epithelium, found in skin or, more commonly, the lining of body organs, for example: breast, ovary, prostate, lung, kidney, pancreas, stomach, bladder or bowel. Cancers tend to infiltrate into adjacent tissue and spread (metastasise) to distant organs, for example: to bone, liver, lung or the brain.
  • the cell may also comprise further polynucleotide sequences encoding one or more further proteins of interest.
  • the recombinant gram-negative bacterial cell according to the present invention may be produced by any suitable means.
  • the recombinant polynucleotide encoding DsbC and/or the polynucleotide encoding the antibody may be integrated into the cell's genome using a suitable vector such as pK03, (Link et al., 1997, Journal of Bacteriology, 179, 6228-6237).
  • the recombinant polynucleotide encoding DsbC and/or the polynucleotide encoding the antibody may be non-integrated in a recombinant expression cassette.
  • an expression cassette is employed in the present invention to carry the polynucleotide encoding DsbC and/or the polynucleotide encoding the antibody which typically comprises a protein coding sequence encoding DsbC, one or more protein coding sequences encoding the antibody and one or more regulatory expression sequences.
  • the one or more regulatory expression sequences may include a promoter.
  • the one or more regulatory expression sequences may also include a 3' untranslated region such as a termination sequence. Suitable promoters are discussed in more detail below.
  • the cell according to the present invention comprises one or more expression vectors, such as plasmid.
  • the vector preferably comprises one or more of the expression cassettes as defined above.
  • the cell preferably comprises a expression vector comprising DNA encoding an antibody or an antigen binding fragment thereof specific for human TNFot as described above.
  • the expression vector comprises a polynucleotide sequence encoding a light chain and a polynucleotide sequence encoding a heavy chain of the antibody.
  • the expression vector is an E. coli expression vector.
  • polynucleotide sequence encoding the antibody and the polynucleotide encoding DsbC are inserted into separate expression vectors.
  • the cell line may be transfected with two vectors, a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide.
  • a single vector may be used, the vector including sequences encoding light chain and heavy chain polypeptides.
  • the polynucleotide sequence encoding the antibody and the polynucleotide encoding DsbC are inserted into one vector.
  • the vector comprises the sequences encoding the light and heavy chain polypeptides of the antibody.
  • the present invention also provides an expression vector comprising a recombinant polynucleotide encoding DsbC and an antibody or an antigen binding fragment thereof specific for human TNFa.
  • the expression vector is a multi-cistronic vector comprising the polynucleotide sequence encoding DsbC and the polynucleotide sequence encoding the antibody.
  • the multicistronic vector may be produced by an advantageous cloning method which allows repeated sequential cloning of polynucleotide sequences into a vector.
  • the method uses compatible cohesive ends of a pair of restrictions sites, such as the "AT" ends of Ase I and Nde I restriction sites.
  • a polynucleotide sequence comprising a coding sequence and having compatible cohesive ends, such as a Asel-Ndel fragment may be cloned into a restrictions site in the vector, such as Nde I.
  • the insertion of the polynucleotide sequence destroys the 5' restriction site but creates a new 3' restriction site, such as Ndel, which may then be used to insert a further polynucleotide sequence comprising compatible cohesive ends.
  • Each polynucleotide sequence inserted into the vector comprises non-coding sequence 3' to the stop codon which may comprise an Ssp I site for screening, a Shine Dalgarno ribosome binding sequence, an A rich spacer and an Ndel site encoding a start codon.
  • a diagrammatic representation of the creation of a vector comprising a polynucleotide sequence encoding a light chain of an antibody (LC), a heavy chain of an antibody (HC), a DsbC polynucleotide sequence and a further polynucleotide sequence is shown in Figure 1.
  • the cell according to the present invention preferably comprises an expression vector as defined above.
  • one or more proteins capable of facilitating protein folding such as FkpA, Skp, SurA, PPiA and PPiD; and/or
  • one or more protein capable of facilitating protein secretion or translocation such as SecY, SecE, SecG, SecYEG, SecA, SecB, FtsY and Lep; and/or
  • one or more proteins capable of facilitating disulphide bond formation such as DsbA, DsbB, DsbD, DsbG;
  • the one or more further protein may be expressed from one or more polynucleotides inserted into the same vector as the polynucleotide encoding DsbC and/or the polynucleotide sequence encoding the antibody.
  • the one or more polynucleotides may be inserted into separate vectors.
  • the expression vector may be produced by inserting one or more expression cassettes as defined above into a suitable vector.
  • the regulatory expression sequences for directing expression of the polynucleotide sequence may be contained in the expression vector and thus only the encoding region of the polynucleotide may be required to complete the expression vector.
  • the polynucleotide encoding DsbC and/or the polynucleotide encoding the antibody is suitably inserted into a replicable vector, typically an autonomously replicating expression vector, for expression in the cell under the control of a suitable promoter for the cell.
  • a replicable vector typically an autonomously replicating expression vector
  • Many vectors are known in the art for this purpose and the selection of the appropriate vector may depend on the size of the nucleic acid and the particularly cell type.
  • expression vectors which may be employed to transform the host cell with a polynucleotide according to the invention include:
  • a plasmid such as pBR322 or pACYCl 84, and/or
  • a viral vector such as bacterial phage • a transposable genetic element such as a transposon
  • Such expression vectors usually comprise a plasmid origin of DNA replication, an antibiotic selectable marker, a promoter and transcriptional terminator separated by a multi-cloning site (expression cassette) and a DNA sequence encoding a ribosome binding site.
  • the promoters employed in the present invention can be linked to the relevant polynucleotide directly or alternatively be located in an appropriate position, for example in a vector such that when the relevant polypeptide is inserted the relevant promoter can act on the same.
  • the promoter is located before the encoding portion of the polynucleotide on which it acts, for example a relevant promoter before each encoding portion of polynucleotide. "Before" as used herein is intended to imply that the promoter is located at the 5 prime end in relation to the encoding polynucleotide portion.
  • the promoters may be endogenous or exogenous to the host cells. Suitable promoters include Lac, tac, trp, PhoA, Ipp, Arab, Tet and T7.
  • One or more promoters employed may be inducible promoters.
  • the nucleotide sequences encoding DsbC and the antibody may be under the control of a single promoter or separate promoters.
  • the promoter may be independently inducible promoters.
  • Promoters for use in bacterial systems also generally contain a Shine-Dalgamo (S.D.) sequence operably linked to the DNA encoding the polypeptide of interest.
  • the promoter can be removed from the bacterial source DNA by restriction enzyme digestion and inserted into the vector containing the desired DNA.
  • the polynucleotide sequence encoding the antibody comprises two or more encoding sequences for an antibody light chain and antibody heavy chain
  • the polynucleotide sequence may comprise one or more internal ribosome entry site (IRES) sequences which allows translation initiation in the middle of an mRNA.
  • IRES internal ribosome entry site
  • An IRES sequence may be positioned between encoding polynucleotide sequences to enhance separate translation of the mRNA to produce the encoded polypeptide sequences.
  • the expression vector preferably also comprises a dicistronic message for producing the antibody or antigen binding fragment thereof as described in WO 03/048208 or WO2007/039714 (the contents of which are incorporated herein by reference).
  • the upstream cistron contains DNA coding for the light chain of the antibody and the downstream cistron contains DNA coding for the corresponding heavy chain
  • the dicistronic intergenic sequence preferably comprises a sequence selected from IGS1 (SEQ ID NO: 23), IGS2 (SEQ ID NO: 24), IGS3 (SEQ ID NO: 25) and IGS4 (SEQ ID NO: 26).
  • the terminators may be endogenous or exogenous to the host cells.
  • a suitable terminator is rrnB .
  • transcriptional regulators including promoters and terminators and protein targeting methods may be found in "Strategies for Achieving High-Level Expression of Genes in Escherichia coli" Sawas C. Makrides, Microbiological Reviews, Sept 1996, p 512-538.
  • the DsbC polynucleotide inserted into the expression vector preferably comprises the nucleic acid encoding the DsbC signal sequence and the DsbC coding sequence.
  • the vector preferably contains a nucleic acid sequence that enables the vector to replicate in one or more selected host cells, preferably to replicate independently of the host chromosome. Such sequences are well known for a variety of bacteria.
  • the DsbC and/or the protein of interest comprises a histidine- tag at the N-terminus and/or C-terminus.
  • the antibody molecule may be secreted from the cell or targeted to the periplasm by suitable signal sequences. Alternatively, the antibody molecules may accumulate within the cell's cytoplasm. Preferably the antibody molecule is targeted to the periplasm.
  • the polynucleotide encoding the antibody may be expressed as a fusion with another polypeptide, preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature polypeptide.
  • the heterologous signal sequence selected should be one that is recognized and processed by the host cell.
  • the signal sequence is substituted by a prokaryotic signal sequence. Suitable signal sequences include OmpA, PhoA, LamB, PelB, DsbA and DsbC.
  • each polynucleotide may comprise a signal sequence, such as OmpA.
  • Plasmids containing one or more of the above-listed components employs standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and re-ligated in the form desired to generate the plasmids required. General methods by which the vectors may be constructed, transfection methods and culture methods are well known to those skilled in the art. In this respect, reference is made to "Current Protocols in Molecular Biology", 1999, F. M. Ausubel (ed), Wiley Interscience, New York and the Maniatis Manual produced by Cold Spring Harbor Publishing.
  • DNA sequences coding for the antibody may be synthesized using standard techniques of molecular biology. Desired DNA sequences may be synthesised completely or in part using oligonucleotide synthesis techniques. Site-directed mutagenesis and polymerase chain reaction (PCR) techniques may be used as appropriate.
  • PCR polymerase chain reaction
  • Embodiments of the invention described herein with reference to the polynucleotide apply equally to alternative embodiments of the invention, for example vectors, expression cassettes and/or host cells comprising the components employed therein, as far as the relevant aspect can be applied to same.
  • the present invention also provides a method for producing an antibody or an antigen binding fragment thereof specific for human TNFa comprising:
  • the gram negative bacterial cell and antibody preferably employed in the method of the present invention are described in detail above.
  • the recombinant polynucleotide encoding DsbC and the polynucleotide encoding the antibody may be incorporated into the host cell using any suitable means known in the art. As discussed above, typically the polynucleotide encoding DsbC and the polynucleotide encoding the antibody are incorporated as part of the same or separate expression vectors which are transformed into the cell.
  • the polynucleotide encoding DsbC and the polynucleotide encoding the antibody can be transformed into a cell using standard techniques, for example employing rubidium chloride, PEG or electroporation.
  • the method according to the present invention may also employ a selection system to facilitate selection of stable cells which have been successfully transformed with the polynucleotide encoding the protein of interest.
  • the selection system typically employs co-transformation of a polynucleotide sequence encoding a selection marker.
  • each polynucleotide transformed into the cell further comprises a polynucleotide sequence encoding one or more selection markers. Accordingly, the transformation of the polynucleotides encoding DsbC and the antibody and the one or more polynucleotides encoding the marker occurs together and the selection system can be employed to select those cells which produce the desired proteins.
  • Cells able to express the one or more markers are able to survive/grow/multiply under certain artificially imposed conditions, for example the addition of a toxin or antibiotic, because of the properties endowed by the polypeptide/gene or polypeptide component of the selection system incorporated therein (e.g. antibiotic resistance). Those cells that cannot express the one or more markers are not able to survive/grow/multiply in the artificially imposed conditions.
  • the artificially imposed conditions can be chosen to be more or less vigorous, as required.
  • any suitable selection system may be employed in the present invention.
  • the selection system may be based on including in the vector one or more genes that provides resistance to a known antibiotic, for example a tetracycline, chloramphenicol, kanamycin or ampicillin resistance gene. Cells that grow in the presence of a relevant antibiotic can be selected as they express both the gene that gives resistance to the antibiotic and the desired protein.
  • An inducible expression system or a constitutive promoter may be used in the present invention to express the antibody and/or the DsbC.
  • Suitable inducible expression systems and constitutive promoters are well known in the art.
  • the expression of the polynucleotide sequence encoding the antibody and the recombinant polynucleotide encoding DsbC is induced by adding an inducer to the culture medium.
  • the medium may be adapted for a specific selection system, for example the medium may comprise an antibiotic, to allow only those cells which have been successfully transformed to grow in the medium.
  • the cells obtained from the medium may be subjected to further screening and/or purification as required.
  • the method may further comprise one or more steps to extract and purify the protein of interest as required.
  • the antibody may be recovered and purified from the strain, including from the cytoplasm, periplasm, or supernatant. Suitable methods include fractionation on immunoaffnity or ion-exchange columns; ethanol precipitation; reversed-phase HPLC; hydrophobic-interaction chromatography; chromatography on silica; chromatography on an ion-exchange resin such as S-SEPHAROSE and DEAE; chromatofocusing; ammonium-sulfate precipitation; and gel filtration.
  • Antibodies may be suitably separated from the culture medium and/or cytoplasm extract and/or periplasm extract by conventional antibody purification procedures such as, for example, protein A-Sepharose, protein G chromatography, protein L chromatograpy, thiophilic, mixed mode resins, Histag, FLAGTag, hydroxylapatite chromatography, gel electrophoresis, dialysis, affinity chromatography, Ammonium Sulphate, ethanol or PEG fractionation/precipitation, ion exchange membranes, expanded bed adsorption chromatography (EBA) or simulated moving bed chromatography.
  • EBA expanded bed adsorption chromatography
  • the method may also include a further step of measuring the quantity of expression of the protein of interest and selecting cells having high expression levels of the protein of interest.
  • One or more method steps described herein may be performed in combination in a suitable container such as a bioreactor.
  • the antibody may be further processed, for example by conjugation to another entity such as an effector molecule.
  • the method according to the present invention may comprise a further step of attaching an effector molecule to the antibody.
  • effector molecule includes, for example, antineoplastic agents, drugs, toxins (such as enzymatically active toxins of bacterial or plant origin and fragments thereof e.g. ricin and fragments thereof) biologically active proteins, for example enzymes, other antibody or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof e.g.
  • Effector molecular may be attached to the antibody or fragment thereof by any suitable method, for example an antibody fragment may be modified to attach at least one effector molecule as described in WO05/003171 or WO05/003170 (the contents of which are incorporated herein by reference). WO05/003171 or WO05/003170 also describe suitable effector molecules.
  • the antibody may have a macrocycle, for chelating a heavy metal atom, or a toxin, such as ricin, attached to it by a covalent bridging structure.
  • procedures of recombinant DNA technology may be used to produce an antibody molecule in which the Fc fragment (CH2, CH3 and hinge domains), the CH2 and CH3 domains or the CH3 domain of a complete immunoglobulin molecule has (have) been replaced by, or has attached thereto by peptide linkage, a functional non-immunoglobulin protein, such as an enzyme or toxin molecule.
  • the additional amino acids preferably form a modified hinge region containing one or two cysteine residues to which the effector or reporter molecule may be attached.
  • a preferred effector group is a polymer molecule, which may be attached to the modified Fab fragment to increase its half-life in vivo.
  • the polymer molecule may, in general, be a synthetic or a naturally occurring polymer, for example an optionally substituted straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymer or a branched or unbranched polysaccharide, e.g. a homo- or hetero- polysaccharide.
  • Particular optional substituents which may be present on the above-mentioned synthetic polymers include one or more hydroxy, methyl or methoxy groups.
  • Particular examples of synthetic polymers include optionally substituted straight or branched chain poly(ethyleneglycol), poly(propyleneglycol) poly(vinylalcohol) or derivatives thereof, especially optionally substituted poly(ethyleneglycol) such as methoxypoly(ethyleneglycol) or derivatives thereof.
  • Particular naturally occurring polymers include lactose, amylose, dextran, glycogen or derivatives thereof.
  • “Derivatives" as used herein is intended to include reactive derivatives, for example thiol- selective reactive groups such as maleimides and the like. The reactive group may be linked directly or through a linker segment to the polymer. It will be appreciated that the residue of such a group will in some instances form part of the product as the linking group between the antibody fragment and the polymer.
  • the size of the polymer may be varied as desired, but will generally be in an average molecular weight range from 500Da to 50000Da, preferably from 5000 to 4000Da and more preferably from 25000 to 4000Da.
  • the polymer size may in particular be selected on the basis of the intended use of the product.
  • a small molecular weight polymer for example with a molecular weight of around 5000Da.
  • a higher molecular weight polymer for example having a molecular weight in the range from 25000Da to 40000Da.
  • Particularly preferred polymers include a polyalkylene polymer, such as a poly(ethyleneglycol) or, especially, a methoxypoly(ethyleneglycol) or a derivative thereof, and especially with a molecular weight in the range from about 25000Da to about 40000Da.
  • a polyalkylene polymer such as a poly(ethyleneglycol) or, especially, a methoxypoly(ethyleneglycol) or a derivative thereof, and especially with a molecular weight in the range from about 25000Da to about 40000Da.
  • Each polymer molecule attached to the modified antibody fragment may be covalently linked to the sulphur atom of a cysteine residue located in the fragment.
  • the covalent linkage will generally be a disulphide bond or, in particular, a sulphur-carbon bond.
  • the antibody fragment may have one or more effector or reporter molecules attached to it.
  • the effector or reporter molecules may be attached to the antibody fragment through any available amino acid side-chain or terminal amino acid functional group located in the fragment, for example any free amino, imino, hydroxyl or carboxyl group.
  • One or more effector or reporter molecules may be attached to an amino acid at or towards the C-terminal end of the heavy chain and/or the light chain of the antibody.
  • An activated polymer may be used as the starting material in the preparation of polymer-modified antibody fragments as described above.
  • the activated polymer may be any polymer containing a thiol reactive group such as an a-halocarboxylic acid or ester, e.g.
  • iodoacetamide an imide, e.g. maleimide, a vinyl sulphone or a disulphide.
  • imide e.g. maleimide
  • vinyl sulphone e.g. vinyl sulphone
  • disulphide e.g. sodium sulfate
  • Such starting materials may be obtained commercially (for example from Shearwater Polymers Inc., Huntsville, AL, USA) or may be prepared from commercially available starting materials using conventional chemical procedures.
  • an antibody fragment linked to an effector or reporter molecule this may be prepared by standard chemical or recombinant DNA procedures in which the antibody fragment is linked either directly or via a coupling agent to the effector or reporter molecule either before or after reaction with the activated polymer as appropriate.
  • Particular chemical procedures include, for example, those described in WO 93/62331, WO 92/22583, WO 90,195 and WO 89/1476.
  • the effector or reporter molecule is a protein or polypeptide the linkage may be achieved using recombinant DNA procedures, for example as described in WO 86/01533 and EP-A- 0392745.
  • the modified Fab fragment provided by the method of the present invention is PEGylated (i.e. has PEG (poly(ethyleneglycol)) covalently attached thereto) according to the method disclosed in EP-A-0948544.
  • the antibody is a PEGylated modified Fab fragment as shown in Figure 2.
  • the modified Fab fragment has attached to one of the cysteine residues at the C-terminal end of the modified hinge region of the heavy chain a lysyl-maleimide-derived group wherein each of the two amino groups of the lysyl residue has covalently linked to it a methoxypoly(ethyleneglycol) residue having a molecular weight of about 20,000 Da, such that the total average molecular weight of the methoxypoly(ethyleneglycol) residues is about 40,000Da, more preferably the lysyl-maleimide-derived group is [l-[[[2-[[[3-(2,5- dioxo-l-pyrrolidinyl)-l-oxopropyl]amino]ethyl]amino]-carbonyl]-l,5- pentanediyl]bis(iminocarbonyl).
  • a lysine residue is covalently linked to the maleimide group.
  • a methoxypoly(ethyleneglycol) polymer having a molecular weight of approximately 20,000 Da. The total molecular weight of the entire effector molecule is therefore approximately 40,000 Da.
  • the method according to the present invention preferably comprises attaching to one of the cysteine residues at the C-terminal end of the heavy chain a lysyl- maleimide group wherein each amino group of the lysyl residue has covalently linked to it a methoxypoly(ethyleneglycol) residue having a molecular weight of about 20,000 Da.
  • the heavy chain of the antibody part has the sequence given as SEQ ID NO :2 land the light chain has the sequence given in SEQ ID NO: 19.
  • This compound is referred to herein as CDP870.
  • one or more E.coli host proteins that in the wild type are known to co-purify with the antibody during purification are selected for genetic modification, as described in Humphreys et al. "Engineering of Escherichia coli to improve the purification of periplasmic Fab' fragments: changing the pi of the chromosomally encoded PhoS/PstS protein", Protein Expression and Purification 37 (2004) 109-118 and WO04/035792 (the contents of which are incorporated herein by reference).
  • the use of such modified host proteins improves the purification process for proteins of interest, especially antibodies, produced in E.col by altering the physical properties of selected E.coli proteins so they no longer co-purify with the recombinant antibody.
  • the E.coli protein that is altered is selected from one or more of Phosphate binding protein (PhoS/PstS), Dipeptide binding protein (DppA), Maltose binding protein (MBP) and Thioredoxin.
  • a physical property of a contaminating host protein is altered by the addition of an amino acid tag to the C-terminus or N-terminus.
  • the physical property that is altered is the isoelectric point and the amino acid tag is a poly-aspartic acid tag attached to the C-terminus.
  • the E.coli proteins altered by the addition of said tag are Dipeptide binding protein (DppA), Maltose binding protein (MBP), Thioredoxin and Phosphate binding protein (PhoS/PstS).
  • the pi of the E.coli Phosphate binding protein is reduced from 7.2 to 5.1 by the addition of a poly-aspartic acid tag (polyD), containing 6 aspartic acid residues to the C-terminus.
  • polyD poly-aspartic acid tag
  • modification of specific residues of the contaminating E. coli protein to alter its physical properties can include insertions or deletions to alter the size of the protein or amino acid substitutions to alter pi or hydrophobicity.
  • these residues are located on the surface of the protein.
  • surface residues of the PhoS protein are altered in order to reduce the pi of the protein.
  • residues that have been implicated to be important in phosphate binding are avoided in order to maintain a functional PhoS protein.
  • lysine residues that project far out of the surface of the protein or are in or near large groups of basic residues are targeted.
  • the PhoS protein has a hexa poly-aspartic acid tag attached to the C-terminus whilst surface residues at the opposite end of the molecule are targeted for substitution.
  • selected lysine residues are substituted for glutamic acid or aspartic acid to confer a greater potential pi change than when changing neutral residues to acidic ones.
  • substitution mutant herein consists of a letter followed by a number followed by a letter.
  • the first letter designates the amino acid in the wild-type protein.
  • the number refers to the amino acid position where the amino acid substitution is being made, and the second letter designates the amino acid that is used to replace the wild-type amino acid.
  • lysine residues (K) 275, 107, 109, 110, 262, 265, 266, 309, 313 are substituted for glutamic acid (E) or glutamine (Q), as single or combined mutations, in addition lysine(K)318 may be substituted for aspartic acid (D) as a single or combined mutation.
  • the single mutations are K262E, K265E and K266E.
  • the combined mutations are K265/266E and Kl 10/265/266E.
  • all mutations are combined with the polyaspartic acid (polyD) tag attached at the C- terminus and optionally also with the K318D substitution.
  • the mutations result in a reduction in pi of at least 2 units.
  • the mutations of the present invention reduce the pi of PhoS from 7.2 to between about 4 and about 5.5.
  • the pi of the PhoS protein of E.coli is reduced from 7.2 to about 4.9, about 4.8 and about 4.5 using the mutations polyD K318D, polyD K265/266E and polyD Kl 10/265/266E respectively.
  • a dicistronic message was created of the anti-TNFa Fab' fragment described in WOO 1/94585.
  • the upstream cistron encoded the light chain of the antibody (SEQ ID NO: 19) whilst the downstream cistron encoded the heavy chain of the antibody (SEQ ID NO: 21).
  • a DNA sequence encoding the OmpA signal peptide was fused to the 5' end of the DNA coding for each of the light chain and the heavy chain to allow efficient secretion to the periplasm.
  • the intergenic sequence (IGS) 2 was used as shown in SEQ ID NO: 24.
  • E.coli cell line W3110 was used as the wild-type cell line.
  • a plasmid was constructed containing both the heavy and light chain sequences of an anti- TNF Fab' and the sequence encoding DsbC (SEQ ID NO:27).
  • Plasmid pDPH358 (pTTO 40.4 CDP870 IGS2), an expression vector for the CDP870 Fab' (an anti-TNF Fab') and DsbC (a periplasmic polypeptide), was constructed using conventional restriction cloning methodologies which can be found in Sambrook et al 1989, Molecular cloning: a laboratory manual. CSHL press, N.Y.
  • the plasmid pDPH358 contained the following features; a strong tac promoter and lac operator sequence. As shown in Figure 1, the plasmid contained a unique EcoRI restriction site after the coding region of the Fab' heavy chain, followed by a non-coding sequence and then a unique Ndel restriction site.
  • the DsbC gene was PCR cloned using W3110 crude chromosomal DNA as a template such that the PCR product encoded for a 5' EcoRI site followed by a strong ribosome binding, followed by the native start codon, signal sequence and mature sequence of DsbC, terminating in a C-terminal His tag and finally a non-coding Ndel site.
  • the EcoRI-Ndel PCR fragment was restricted and ligated into the expression vector such that all three polypeptides: Fab' light chain, Fab' heavy chain and DsbC were encoded on a single polycistronic mRNA.
  • the Fab light chain, heavy chain genes and DcbC gene were transcribed as a single polycistronic message.
  • DNA encoding the signal peptide from the E. coli OmpA protein was fused to the 5' end of both light and heavy chain gene sequences, which directed the translocation of the polypeptides to the E. coli periplasm. Transcription was terminated using a dual transcription terminator rrnB tlt2.
  • the laclq gene encoded the constitutively expressed Lac I repressor protein. This repressed transcription from the tac promoter until de-repression was induced by the presence of allolactose or IPTG.
  • the origin of replication used was pi 5 A, which maintained a low copy number.
  • the plasmid contained a tetracycline resistance gene for antibiotic selection.
  • the E.coli W3110 cell strain was transformed with the plasmid generated in Example 1.
  • the transformation of the strains was carried out using the method found in Chung C.T et al Transformation and storage of bacterial cells in the same solution. PNAS 86:2172-2175 (1989).
  • the E. coli W3110 cell strain was transformed with plasmid pMXE 117 (pTTO CDP870 or 40.4 IGS2), an expression vector for the anti-TNFa Fab', which was constructed using conventional restriction cloning methodologies which can be found in Sambrook et al 1989, Molecular cloning: a laboratory manual. CSHL press, N.Y.
  • the plasmid pMXEl 17 (pTTO CDP870 or 40.4 IGS2) contained the following features; a strong tac promoter and lac operator sequence.
  • the Fab light and heavy chain genes were transcribed as a single dicistronic message. DNA encoding the signal peptide from the E.
  • coli OmpA protein was fused to the 5' end of both light and heavy chain gene sequences, which directed the translocation of the polypeptides to the E. coli periplasm. Transcription was terminated using a dual transcription terminator rrnB tlt2.
  • the laclq gene encoded the constitutively expressed Lac I repressor protein. This repressed transcription from the tac promoter until de-repression was induced by the presence of allolactose or IPTG.
  • the origin of replication used was pi 5 A, which maintained a low copy number.
  • the plasmid contained a tetracycline resistance gene for antibiotic selection. The transformation of the strains was carried out using the method found in Chung C.T et al Transformation and storage of bacterial cells in the same solution. PNAS 86:2172-2175 (1989).
  • Example 3 Growth of mutated E. coli strains and expression of anti-TNF Fab' in mutated E. coli strains using high density fermentations
  • Example 2 The strains produced in Example 2 were tested in fermentation experiments comparing growth and expression of an anti-TNFoc Fab':
  • the fermentation growth medium was based on SM6E medium (described in Humphreys et al, 2002, Protein Expression and Purification, 26, 309-320) with 3.86 g/1 NaH 2 P0 4 .H 2 0 and 112 g/1 glycerol.
  • Inoculum cultures were grown in the same medium supplemented with 10 ⁇ g/ml tetracycline. Cultures were incubated at 30°C with agitation for approximately 22 hours. Fermentation. Fermenters (2.5 litres total volume) were seeded with inoculum culture to 0.3-0.5 OD 6 oo. Temperature was maintained at 30°C during the growth phase and was reduced to 25 °C prior to induction. The dissolved oxygen concentration was maintained above 30% air saturation by variable agitation and airflow. Culture pH was controlled at 7.0 by automatic titration with 15% (v/v) NH 4 OH and 10% (v/v) cone. H 2 S0 4 .
  • Foaming was controlled by the addition of 10% (v/v) Struktol J673 solution (Schill and Seilacher). A number of additions were made at different stages of the fermentation. When biomass concentration reached approximately 40 OD 60 o, magnesium salts and NaH 2 P0 4 .H 2 0 were added. Further additions of NaH 2 P0 4 .H 2 0 were made prior to and during the induction phase to ensure phosphate was maintained in excess. When the glycerol present at the beginning of fermentation had depleted (approximately 75 OD 600 ) a continuous feed of 80% (w/w) glycerol was applied. At the same point in the fermentation an IPTG feed at 170 ⁇ was applied.
  • the start of IPTG feeding was taken as the start of induction. Fermentations were typically run for 64-120 hours at glycerol feed rates (ranging between 0.5 and 2.5 ml/h). Measurement of biomass concentration and growth rate. Biomass concentration was determined by measuring the optical density of cultures at 600 ran.
  • Fab' quantification Fab' concentrations in periplasmic extracts and culture supernatants were determined by Fab' assembly ELISA as described in Humphreys et ah, 2002, Protein Expression and Purification, 26, 309-320 and using Protein G hplc.
  • a HiTrap Protein-G HP 1ml column (GE-Healthcare or equivalent) was loaded with analyte (approximately neutral pH, 30°C, 0.2um filtered) at 2ml/min, the column was washed with 20mM phosphate, 50mM NaCl pH 7.4 and then Fab' eluted using an injection of 50mM Glycine/HCl pH 2.7.
  • Eluted Fab' was measured by A280 on a Agilent 1100 or 1200 HPLC system and quantified by reference to a standard curve of a purified Fab' protein of known concentration.
  • Figure 3 shows the growth profile of anti-TNF Fab' expressing strain W3110 and the growth profile of anti-TNFa Fab' and recombinant DsbC expressing strain W3110. It can be seen that the strains expressing DsbC exhibit improved growth compared to the corresponding cell strains which do not express recombinant DsbC.
  • Figure 4 shows anti-TNFa Fab' yield from the periplasm (shaded symbols) and supernatant (open unshaded symbols) from the anti-TNFa Fab' expressing strain W3110 and the anti-TNF Fab' and recombinant DsbC expressing strain W3110. It can be seen from this graph that the strain expressing DsbC produced a higher yield of anti-TNFa Fab' compared to the strain which did not express DsbC, with strains W3110 DsbC producing over 3 g/L periplasmic anti-TNFa Fab' in just over 75 hours.
  • the present invention also provides a therapeutic or diagnostic composition comprising the antibody produced by the method of the present invention in combination with a pharmaceutically acceptable excipient, diluent or carrier.
  • the present invention also provides a process for preparation of a therapeutic or diagnostic composition comprising admixing the antibody produced by the method of the present invention together with a pharmaceutically acceptable excipient, diluent or carrier.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne une cellule bactérienne recombinante à Gram négatif comprenant : a. un polynucléotide recombinant codant pour DsbC ; et b. une séquence polynucléotidique codant pour un anticorps ou un fragment de liaison à l'antigène de celui-ci spécifique du TNFα humain.
PCT/EP2011/050418 2010-01-14 2011-01-13 Souche hôte bactérienne exprimant dsbc recombinant WO2011086141A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1000588.2 2010-01-14
GB201000588A GB201000588D0 (en) 2010-01-14 2010-01-14 Bacterial host strain

Publications (1)

Publication Number Publication Date
WO2011086141A1 true WO2011086141A1 (fr) 2011-07-21

Family

ID=42028358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/050418 WO2011086141A1 (fr) 2010-01-14 2011-01-13 Souche hôte bactérienne exprimant dsbc recombinant

Country Status (2)

Country Link
GB (1) GB201000588D0 (fr)
WO (1) WO2011086141A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012013930A3 (fr) * 2010-07-27 2012-05-03 Ucb Pharma S.A. Procédé de purification de protéines
EP2546267A1 (fr) * 2011-07-13 2013-01-16 UCB Pharma S.A. Souche hôte bactérienne exprimant un DsbC recombinant
WO2013007388A1 (fr) * 2011-07-13 2013-01-17 Ucb Pharma, S.A. Souche hôte bactérienne exprimant un dsbc recombiné
US9493558B2 (en) 2010-01-14 2016-11-15 Ucb Pharma, S.A. Bacterial host strain comprising a mutant SPR gene and a wild-type TSP gene
US9493559B2 (en) 2010-01-14 2016-11-15 Ucb Pharma, S.A. Bacterial host strain expressing recombinant DsbC and having reduced Tsp activity
US9550973B2 (en) 2009-09-24 2017-01-24 Ucb Pharma, S.A. Bacterial host strain
US9587227B2 (en) 2010-01-14 2017-03-07 Ucb Pharma, S.A. Bacterial host strain comprising a mutant spr gene and having reduced Tsp activity
US9951365B2 (en) 2012-05-14 2018-04-24 Ucb Biophara Sprl Recombinant bacterial host cell for protein expression
US10487136B2 (en) 2010-02-03 2019-11-26 Ucb Biopharma Sprl Process for obtaining antibodies
CN113260626A (zh) * 2018-11-05 2021-08-13 豪夫迈·罗氏有限公司 在原核宿主细胞中产生双链蛋白质的方法

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001533A1 (fr) 1984-09-03 1986-03-13 Celltech Limited Production d'anticorps chimeriques
WO1989001476A1 (fr) 1987-08-12 1989-02-23 Celltech Limited Macrocycles tetra-aza et complexes metalliques de tels macrocycles
WO1990000195A1 (fr) 1988-06-30 1990-01-11 Xandra Breakefield Adn codant le type a d'oxydase monoaminee humaine
EP0392745A2 (fr) 1989-04-05 1990-10-17 Celltech Limited Immunoconjuguées et prodrogues et leurs applications en association pour la délivrance des médicaments
WO1992022583A2 (fr) 1991-06-11 1992-12-23 Celltech Limited Proteines monospecifiques tri- et tetravalentes de liaison aux antigenes
WO1993012231A1 (fr) 1991-12-13 1993-06-24 Dow Chemical (Australia) Limited Composites de la chaine legere du sous-groupe humain iv aptes a la liaison avec tag-72
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
EP0786009A1 (fr) 1994-11-03 1997-07-30 Genentech, Inc. Procede de production par des bacteries de polypeptides heterologues a liaisons disulphures
WO1998056930A2 (fr) 1997-06-09 1998-12-17 Board Of Regents, The University Of Texas System Procedes de production de polypeptides a ponts disulfure heterologues dans des cellules bacteriennes
EP0948544A1 (fr) 1996-12-10 1999-10-13 Celltech Therapeutics Limited Fragments d'anticorps monovalents
WO2001094585A1 (fr) 2000-06-06 2001-12-13 Celltech R & D Limited Molecules d'anticorps a specificite pour le facteur alpha de necrose tumorale humaine, et leurs utilisations
WO2002061090A2 (fr) * 2000-12-14 2002-08-08 Genentech, Inc. Anticorps produits de maniere procaryote et utilisations de ceux-ci
WO2003018771A2 (fr) * 2001-08-27 2003-03-06 Genentech, Inc. Systeme d'expression d'anticorps et ensemble
WO2003048208A2 (fr) 2001-12-05 2003-06-12 Celltech R & D Limited Regulation d'expression au moyen de sequences intergeniques variables
US6673569B1 (en) 1998-09-09 2004-01-06 Hsp Research Institute, Inc. DsbA/DsbB/DsbC/DsbD expression plasmid
WO2004035792A1 (fr) 2002-10-16 2004-04-29 Celltech R & D Limited Cellules hotes e. coli comprenant des proteines a liaison phosphate periplasmiques phos/psts modifiees et procede de production de fabs recombinants
WO2005003171A2 (fr) 2003-07-01 2005-01-13 Celltech R & D Limited Fragments d'anticorps modifies
WO2005003170A2 (fr) 2003-07-01 2005-01-13 Celltech R & D Limited Fragments d'anticorps modifies
WO2007039714A1 (fr) 2005-10-04 2007-04-12 Ucb Pharma S.A. Controle d'expression a l'aide de sequences d'optimisation d'expression d'anticorps
WO2009026131A2 (fr) * 2007-08-16 2009-02-26 Neose Technologies, Inc. Vecteurs et procédés permettant une meilleure expression de protéines eucaryotes dans des bactéries
WO2009073805A2 (fr) * 2007-12-04 2009-06-11 Verdezyne, Inc. Anticorps thérapeutiques aglycosylés et séquences nucléotidiques codant les anticorps thérapeutiques

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001533A1 (fr) 1984-09-03 1986-03-13 Celltech Limited Production d'anticorps chimeriques
WO1989001476A1 (fr) 1987-08-12 1989-02-23 Celltech Limited Macrocycles tetra-aza et complexes metalliques de tels macrocycles
WO1990000195A1 (fr) 1988-06-30 1990-01-11 Xandra Breakefield Adn codant le type a d'oxydase monoaminee humaine
EP0392745A2 (fr) 1989-04-05 1990-10-17 Celltech Limited Immunoconjuguées et prodrogues et leurs applications en association pour la délivrance des médicaments
WO1992022583A2 (fr) 1991-06-11 1992-12-23 Celltech Limited Proteines monospecifiques tri- et tetravalentes de liaison aux antigenes
WO1993012231A1 (fr) 1991-12-13 1993-06-24 Dow Chemical (Australia) Limited Composites de la chaine legere du sous-groupe humain iv aptes a la liaison avec tag-72
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
EP0786009A1 (fr) 1994-11-03 1997-07-30 Genentech, Inc. Procede de production par des bacteries de polypeptides heterologues a liaisons disulphures
EP0948544A1 (fr) 1996-12-10 1999-10-13 Celltech Therapeutics Limited Fragments d'anticorps monovalents
WO1998056930A2 (fr) 1997-06-09 1998-12-17 Board Of Regents, The University Of Texas System Procedes de production de polypeptides a ponts disulfure heterologues dans des cellules bacteriennes
US6673569B1 (en) 1998-09-09 2004-01-06 Hsp Research Institute, Inc. DsbA/DsbB/DsbC/DsbD expression plasmid
WO2001094585A1 (fr) 2000-06-06 2001-12-13 Celltech R & D Limited Molecules d'anticorps a specificite pour le facteur alpha de necrose tumorale humaine, et leurs utilisations
WO2002061090A2 (fr) * 2000-12-14 2002-08-08 Genentech, Inc. Anticorps produits de maniere procaryote et utilisations de ceux-ci
WO2003018771A2 (fr) * 2001-08-27 2003-03-06 Genentech, Inc. Systeme d'expression d'anticorps et ensemble
WO2003048208A2 (fr) 2001-12-05 2003-06-12 Celltech R & D Limited Regulation d'expression au moyen de sequences intergeniques variables
WO2004035792A1 (fr) 2002-10-16 2004-04-29 Celltech R & D Limited Cellules hotes e. coli comprenant des proteines a liaison phosphate periplasmiques phos/psts modifiees et procede de production de fabs recombinants
WO2005003171A2 (fr) 2003-07-01 2005-01-13 Celltech R & D Limited Fragments d'anticorps modifies
WO2005003170A2 (fr) 2003-07-01 2005-01-13 Celltech R & D Limited Fragments d'anticorps modifies
WO2007039714A1 (fr) 2005-10-04 2007-04-12 Ucb Pharma S.A. Controle d'expression a l'aide de sequences d'optimisation d'expression d'anticorps
WO2009026131A2 (fr) * 2007-08-16 2009-02-26 Neose Technologies, Inc. Vecteurs et procédés permettant une meilleure expression de protéines eucaryotes dans des bactéries
WO2009073805A2 (fr) * 2007-12-04 2009-06-11 Verdezyne, Inc. Anticorps thérapeutiques aglycosylés et séquences nucléotidiques codant les anticorps thérapeutiques

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Chemistry and Biological Applications", 1997, AMERICAN CHEMICAL SOCIETY
"Chemistry, Biotechnical and Biomedical Applications", 1992, PLENUM PRESS
"Current Protocols in Molecular Biology", 1999, WILEY INTERSCIENCE
"Maniatis Manual produced", COLD SPRING HARBOR PUBLISHING
BACKLUND E.; REEKS D.; MARKLAND K.; WEIR N.; BOWERING L.; LARSSON G.: "Fedbatch design for periplasmic product retention in Escherichia coli, Journal Article Research Support", NON-U.S. GOV'T JOURNAL OF BIOTECHNOLOGY, vol. 135, no. 4, 31 July 2008 (2008-07-31), pages 358 - 365
CHAMPION KM.; NISHIHARA JC.; JOLY JC.; ARNOTT D.: "Similarity of the Escherichia coli proteome upon completion of different biopharmaceutical fermentation processes", PROTEOMICS., vol. 1, no. 9, September 2001 (2001-09-01), pages 1133 - 1148
CHUNG C.T ET AL.: "Transformation and storage of bacterial cells in the same solution", PNAS, vol. 86, 1989, pages 2172 - 2175
CRAMERI ET AL., NATURE, vol. 391, 1998, pages 288 - 291
HEO M A ET AL: "Functional expression of single-chain variable fragment antibody against c-Met in the cytoplasm of Escherichia coli", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, vol. 47, no. 1, 1 May 2006 (2006-05-01), pages 203 - 209, XP024908731, ISSN: 1046-5928, [retrieved on 20060501], DOI: DOI:10.1016/J.PEP.2005.12.003 *
HORN U.; STRITTMATTER W.; KREBBER A.; KNUPFER U.; KUJAU M.; WENDEROTH R.; MULLER K.; MATZKU S.; PLUCKTHUN A.; RIESENBERG D.: "High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high- cell-density fermentation under non-limited growth conditions Journal Article. Research Support", NON-U.S. GOV'T APPLIED MICROBIOLOGY & BIOTECHNOLOGY, vol. 46, no. 5-6, 1996, pages 524 - 532
HU ET AL: "Cloning, expression and characterisation of a single-chain Fv antibody fragment against domoic acid in Escherichia coli", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 120, no. 1, 17 October 2005 (2005-10-17), pages 38 - 45, XP005097884, ISSN: 0168-1656, DOI: DOI:10.1016/J.JBIOTEC.2005.05.018 *
HUMPHREYS D P ET AL.: "Formation of dimeric Fabs in E. coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab' expression levels, tail piece sequences and growth conditions", J IMMUNOL. METH., vol. 209, 1997, pages 193 - 202
HUMPHREYS ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 26, 2002, pages 309 - 320
HUMPHREYS ET AL.: "Engineering of Escherichia coli to improve the purification of periplasmic Fab' fragments: changing the pI of the chromosomally encoded PhoS/PstS protein", PROTEIN EXPRESSION AND PURIFICATION, vol. 37, 2004, pages 109 - 118
LINK ET AL., JOURNAL OF BACTERIOLOGY, vol. 179, 1997, pages 6228 - 6237
LOW ET AL., J. MOL. BIOL., vol. 250, 1996, pages 359 - 368
M. ASLAM; A. DENT: "Bioconjugation Protein Coupling Techniques for the Biomedical Sciences", 1998, GROVE PUBLISHERS
MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783
MASKOS K ET AL: "DsbA and DsbC-catalyzed Oxidative Folding of Proteins with Complex Disulfide Bridge Patterns In Vitro and In Vivo", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 325, no. 3, 17 January 2003 (2003-01-17), pages 495 - 513, XP027180830, ISSN: 0022-2836, [retrieved on 20030117] *
MISSIAKAS ET AL.: "The Escherichia coli dsbC (xprA) gene encodes a periplasmic protein involved in disulfide bond formation", THE EMBO JOURNAL, vol. 13, no. 8, 1994, pages 2013 - 2020
PATTEN ET AL., CURR. OPIN. BIOTECHNOL., vol. 8, 1997, pages 724 - 733
SAMBROOK ET AL.: "Molecular cloning: a laboratory manual", 1989, CSHL PRESS
SAVVAS C. MAKRIDES: "Strategies for Achieving High-Level Expression of Genes in Escherichia coli", MICROBIOLOGICAL REVIEWS, September 1996 (1996-09-01), pages 512 - 538
SHEVCHIK ET AL.: "Characterization of DsbC, a periplasmic protein of Erwinia chrysanthemi and Escherichia coli with disulfide isomerase activity", THE EMBO JOURNAL, vol. 13, no. 8, 1994, pages 2007 - 2012
THOMPSON ET AL., J. MOL. BIOL., vol. 256, 1996, pages 77 - 88
YANG ET AL., J. MOL. BIOL., vol. 254, 1995, pages 392 - 403

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550973B2 (en) 2009-09-24 2017-01-24 Ucb Pharma, S.A. Bacterial host strain
US9587227B2 (en) 2010-01-14 2017-03-07 Ucb Pharma, S.A. Bacterial host strain comprising a mutant spr gene and having reduced Tsp activity
US9493558B2 (en) 2010-01-14 2016-11-15 Ucb Pharma, S.A. Bacterial host strain comprising a mutant SPR gene and a wild-type TSP gene
US9493559B2 (en) 2010-01-14 2016-11-15 Ucb Pharma, S.A. Bacterial host strain expressing recombinant DsbC and having reduced Tsp activity
US11384136B2 (en) 2010-02-03 2022-07-12 UCB Biopharma SRL Process for obtaining antibodies
US10487136B2 (en) 2010-02-03 2019-11-26 Ucb Biopharma Sprl Process for obtaining antibodies
US9751930B2 (en) 2010-07-27 2017-09-05 Ucb Pharma, S.A. Process for purifying proteins
WO2012013930A3 (fr) * 2010-07-27 2012-05-03 Ucb Pharma S.A. Procédé de purification de protéines
US9725516B2 (en) 2011-07-13 2017-08-08 Ucb Pharma, S.A. Bacterial host strain expressing recombinant DSBC
US9957328B2 (en) 2011-07-13 2018-05-01 Ucb Pharma, S.A. Bacterial host strain expressing recombinant DSBC
EP3339325A1 (fr) * 2011-07-13 2018-06-27 UCB Biopharma SPRL Souche hôte bactérienne exprimant un dsbc recombinant
EA031449B1 (ru) * 2011-07-13 2019-01-31 Юсб Фарма, С.А. Бактериальный штамм-акцептор, экспрессирующий рекомбинантный dsbc
WO2013007388A1 (fr) * 2011-07-13 2013-01-17 Ucb Pharma, S.A. Souche hôte bactérienne exprimant un dsbc recombiné
EP2546267A1 (fr) * 2011-07-13 2013-01-16 UCB Pharma S.A. Souche hôte bactérienne exprimant un DsbC recombinant
US9951365B2 (en) 2012-05-14 2018-04-24 Ucb Biophara Sprl Recombinant bacterial host cell for protein expression
US11261470B2 (en) 2012-05-14 2022-03-01 UCB Biopharma SRL Recombinant bacterial host cell for protein expression
CN113260626A (zh) * 2018-11-05 2021-08-13 豪夫迈·罗氏有限公司 在原核宿主细胞中产生双链蛋白质的方法

Also Published As

Publication number Publication date
GB201000588D0 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
AU2017202434B2 (en) Bacterial host strain expressing recombinant DsbC and having reduced Tsp activity
US9957328B2 (en) Bacterial host strain expressing recombinant DSBC
WO2011086141A1 (fr) Souche hôte bactérienne exprimant dsbc recombinant
US9587227B2 (en) Bacterial host strain comprising a mutant spr gene and having reduced Tsp activity
AU2017200545B2 (en) Bacterial host strain comprising a mutant spr gene and a wild-type Tsp gene
EP2546267A1 (fr) Souche hôte bactérienne exprimant un DsbC recombinant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11700145

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11700145

Country of ref document: EP

Kind code of ref document: A1